Search results for: 'Small Molecule Contract Development and Manufacturing Organization'

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essen...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

Organic solar cells (OSCs) are emerging as one of the more versatile photovoltaic technologies inthe third-generation solar cell technology domain, owing to their unique characteristics of flexibility, ultralightweight form factors, low-temperature processing, and compatibility with high-throughput printing techniques. Advancements in donor–accepto...

10 Sep 2024  |  Global  |  Technology Research

Technology Advances in Modular and Automated Platforms for Pharmaceutical Manufacturing

Increasing demand for small molecule drugs is driving the growth of modular and automated technologies in pharmaceutical manufacturing

Infographics

×

This study examines technology advances in modular and automated platforms for non-biologics manufacturing in the pharmaceutical sector. There is a growing demand for automated and modular technologies that ensure regulatory compliance, increase productivity, reduce waste, and meet emerging therapeutic requirements such as those of the personalized...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...